Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Rodrigo E Mendes

Showing results (41-50 of 278) with videos related to

Pageof 28
Sort By:
Diagnostic Microbiology and Infectious Disease|February 18, 2010
Spectrum of activity, mutation rates, synergistic interactions, and the effects of pH and serum proteins for fusidic acid (CEM-102)Douglas J Biedenbach, Paul R Rhomberg, Rodrigo E Mendes, et al.
The Journal of Infection|May 17, 2017
Empyema thoracis caused by an optrA-positive and linezolid-intermediate Enterococcus faecalis strainJung-Yien Chien, Rodrigo E Mendes, Lalitagauri M Deshpande, et al.
Diagnostic Microbiology and Infectious Disease|November 17, 2009
Linezolid surveillance program results for 2008 (LEADER Program for 2008)David J Farrell, Rodrigo E Mendes, James E Ross, et al.
Antimicrobial Agents and Chemotherapy|June 13, 2012
Molecular epidemiology of Staphylococcus epidermidis clinical isolates from U.S. hospitalsRodrigo E Mendes, Lalitagauri M Deshpande, Andrew J Costello, et al.
Diagnostic Microbiology and Infectious Disease|September 27, 2012
Update on antimicrobial susceptibility trends among Streptococcus pneumoniae in the United States: report of ceftaroline activity from the SENTRY Antimicrobial Surveillance Program (1998-2011)Ronald N Jones, Helio S Sader, Rodrigo E Mendes, et al.
The Journal of Antimicrobial Chemotherapy|February 13, 2019
Antimicrobial activity of dalbavancin tested against Gram-positive organisms isolated from patients with infective endocarditis in US and European medical centresHelio S Sader, Rodrigo E Mendes, Michael A Pfaller, et al.
Jac-Antimicrobial Resistance|September 8, 2022
Five-year analysis of the <i>in vitro</i> activity of tedizolid against a worldwide collection of indicated species causing clinical infections: results from the Surveillance of Tedizolid Activity and Resistance (STAR) programmeCecilia G Carvalhaes, Helio S Sader, Jennifer M Streit, et al.
Diagnostic Microbiology and Infectious Disease|November 15, 2011
Telavancin activity tested against a contemporary collection of Gram-positive pathogens from USA Hospitals (2007-2009)Rodrigo E Mendes, Helio S Sader, David J Farrell, et al.
Diagnostic Microbiology and Infectious Disease|August 20, 2011
Update on the telavancin activity tested against European staphylococcal clinical isolates (2009-2010)Rodrigo E Mendes, Helio S Sader, David J Farrell, et al.
Diagnostic Microbiology and Infectious Disease|November 28, 2018
In vitro activity of telavancin against Staphylococcus aureus causing pneumonia or skin and skin structure infections with concomitant bloodstream infections in United States hospitals (2012-2016)Leonard R Duncan, Robert K Flamm, Helio S Sader, et al.
Pageof 28

Showing results (41-50 of 278) with videos related to

Sort By:
Pageof 28
Diagnostic Microbiology and Infectious Disease|February 18, 2010
Spectrum of activity, mutation rates, synergistic interactions, and the effects of pH and serum proteins for fusidic acid (CEM-102)Douglas J Biedenbach, Paul R Rhomberg, Rodrigo E Mendes, et al.
The Journal of Infection|May 17, 2017
Empyema thoracis caused by an optrA-positive and linezolid-intermediate Enterococcus faecalis strainJung-Yien Chien, Rodrigo E Mendes, Lalitagauri M Deshpande, et al.
Diagnostic Microbiology and Infectious Disease|November 17, 2009
Linezolid surveillance program results for 2008 (LEADER Program for 2008)David J Farrell, Rodrigo E Mendes, James E Ross, et al.
Antimicrobial Agents and Chemotherapy|June 13, 2012
Molecular epidemiology of Staphylococcus epidermidis clinical isolates from U.S. hospitalsRodrigo E Mendes, Lalitagauri M Deshpande, Andrew J Costello, et al.
Diagnostic Microbiology and Infectious Disease|September 27, 2012
Update on antimicrobial susceptibility trends among Streptococcus pneumoniae in the United States: report of ceftaroline activity from the SENTRY Antimicrobial Surveillance Program (1998-2011)Ronald N Jones, Helio S Sader, Rodrigo E Mendes, et al.
The Journal of Antimicrobial Chemotherapy|February 13, 2019
Antimicrobial activity of dalbavancin tested against Gram-positive organisms isolated from patients with infective endocarditis in US and European medical centresHelio S Sader, Rodrigo E Mendes, Michael A Pfaller, et al.
Jac-Antimicrobial Resistance|September 8, 2022
Five-year analysis of the <i>in vitro</i> activity of tedizolid against a worldwide collection of indicated species causing clinical infections: results from the Surveillance of Tedizolid Activity and Resistance (STAR) programmeCecilia G Carvalhaes, Helio S Sader, Jennifer M Streit, et al.
Diagnostic Microbiology and Infectious Disease|November 15, 2011
Telavancin activity tested against a contemporary collection of Gram-positive pathogens from USA Hospitals (2007-2009)Rodrigo E Mendes, Helio S Sader, David J Farrell, et al.
Diagnostic Microbiology and Infectious Disease|August 20, 2011
Update on the telavancin activity tested against European staphylococcal clinical isolates (2009-2010)Rodrigo E Mendes, Helio S Sader, David J Farrell, et al.
Diagnostic Microbiology and Infectious Disease|November 28, 2018
In vitro activity of telavancin against Staphylococcus aureus causing pneumonia or skin and skin structure infections with concomitant bloodstream infections in United States hospitals (2012-2016)Leonard R Duncan, Robert K Flamm, Helio S Sader, et al.
Pageof 28